Gross profit for 2024 dropped to $0.5 million ... previously expensed to research and development expenses prior to FDA approval of the 365-day product. Fourth quarter 2024 selling, general ...

ANI Pharmaceuticals (ANIP) announced that the U.S. FDA has approved an expanded label for Iluvien that includes an indication for the treatment ...

Stereotaxis targets growth with 2025 product milestones, MAGiC Sweep revenue, and EMAGIN 5F innovation, setting the stage for ...

Financial income, net for the fourth quarter of 2024 was $252,000, a decrease of $216,000 or 46.1% compared to $468,000 for the fourth quarter of 2023. This decrease was primarily due to less interest ...

The gross margin improved significantly from 25% in the fourth quarter of 2023 to 37% in the fourth quarter of 2024. This expansion in profitability helped ImmuCell swing to a net income of $ ...

Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, AscensiaPatient ...